Brenna Maria Keller, DO
Infectious Disease · Cape Girardeau, MONPI 1932261104
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 29.0% of the total. Reporting peaked in 2024 at $868 and has fallen 69.8% since, to $262 in 2025.
Across 177 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Viiv Healthcare Company$513
- Merck$293
- Lilly USA, LLC$251
- Gilead$189
- Aimmune Therapeutics, Inc.$163
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,46698%
- Education$872%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 55 | $1,030 |
| Viiv Healthcare Company | 22 | $513 |
| Merck | 14 | $293 |
| Lilly USA, LLC | 10 | $251 |
| Gilead | 6 | $189 |
| Aimmune Therapeutics, Inc. | 8 | $163 |
| Amarin Pharma, Inc. | 7 | $137 |
| Novo Nordisk | 7 | $119 |
| Pfizer | 6 | $103 |
| Insmed, Inc. | 5 | $88 |
| Madrigal Pharmaceuticals | 1 | $86 |
| Boehringer Ingelheim | 5 | $86 |
| Johnson & Johnson | 4 | $82 |
| EMD Serono, Inc. | 4 | $57 |
| Sunovion Pharmaceuticals Inc. | 4 | $56 |
| AstraZeneca | 4 | $55 |
| Paratek Pharmaceuticals, Inc. | 3 | $53 |
| Mylan Specialty L.p. | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Mylan Institutional Inc. | 1 | $20 |
| Exact Sciences | 1 | $20 |
| Eisai Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| GSK | 1 | $13 |
| Nabriva Therapeutics, PLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,553 in reported general payments places this provider in the 75th percentile of 177 infectious disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 97 | $410,914 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 46 | $180,269 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 42 | $157,995 |
| DescovyEmtricitabine/Tenofov Alafenam | 40 | $112,413 |
| JulucaDolutegravir/Rilpivirine | 18 | $62,576 |
| OzempicSemaglutide | 62 | $59,200 |
| PrezcobixDarunavir/Cobicistat | 23 | $56,412 |
| DovatoDolutegravir Sodium/Lamivudine | 18 | $54,293 |
| Isentress HdRaltegravir Potassium | 17 | $47,625 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 11 | $39,090 |
| VemlidyTenofovir Alafenamide | 24 | $38,477 |
| EvotazAtazanavir Sulfate/Cobicistat | 13 | $20,985 |
| MounjaroTirzepatide | 15 | $15,930 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 27 | $11,889 |
| TradjentaLinagliptin | 27 | $7,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy, Vemlidy | $189 | $742,073207 claims |
| Viiv Healthcare CompanyTriumeq, Juluca, Dovato | $513 | $274,86478 claims |
| Novo NordiskOzempic | $119 | $59,20062 claims |
| Johnson & JohnsonPrezcobix | $82 | $56,41223 claims |
| MerckIsentress Hd, Januvia | $293 | $54,05028 claims |
| Lilly USA, LLCMounjaro | $251 | $15,93015 claims |
| Boehringer IngelheimTradjenta | $86 | $7,08927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 177 infectious disease providers in Missouri.
Other infectious disease in Cape Girardeau
- Charles LavalleCape Girardeau$4K
- Robert BelsheSaint Louis$382K
- Erik DubberkeSaint Louis$144K
- Rupa PatelSaint Louis$96K
- Michael DiamondSaint Louis$44K
- Nirmol PhilipChesterfield$31K
- Andrej SpecSaint Louis$26K
- William PowderlySaint Louis$20K
- Daniel HoftSt Louis$20K
- Matthew GermanChesterfield$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.